Dimensional Fund Advisors LP Has $22.88 Million Position in Emergent Biosolutions Inc. $EBS

Dimensional Fund Advisors LP grew its holdings in Emergent Biosolutions Inc. (NYSE:EBS) by 22.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,757,158 shares of the biopharmaceutical company’s stock after purchasing an additional 504,553 shares during the quarter. Dimensional Fund Advisors LP owned about 5.34% of Emergent Biosolutions worth $22,884,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Millennium Management LLC grew its stake in Emergent Biosolutions by 68.9% during the first quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock worth $12,162,000 after purchasing an additional 1,020,582 shares during the period. Goldman Sachs Group Inc. lifted its stake in Emergent Biosolutions by 12.5% in the first quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company’s stock valued at $5,301,000 after buying an additional 121,583 shares during the period. Legal & General Group Plc acquired a new position in Emergent Biosolutions in the second quarter valued at approximately $31,000. Rhumbline Advisers boosted its holdings in shares of Emergent Biosolutions by 862.4% during the 2nd quarter. Rhumbline Advisers now owns 84,025 shares of the biopharmaceutical company’s stock worth $536,000 after buying an additional 75,294 shares in the last quarter. Finally, Jump Financial LLC bought a new position in shares of Emergent Biosolutions during the 2nd quarter worth approximately $352,000. 78.40% of the stock is owned by institutional investors and hedge funds.

Emergent Biosolutions Trading Down 29.6%

NYSE:EBS opened at $5.31 on Friday. The company has a debt-to-equity ratio of 1.10, a current ratio of 4.29 and a quick ratio of 2.08. The firm has a 50-day moving average of $7.90 and a 200-day moving average of $8.79. The company has a market cap of $273.97 million, a PE ratio of -1.50 and a beta of 2.35. Emergent Biosolutions Inc. has a one year low of $5.06 and a one year high of $14.06.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.68. The business had revenue of $234.30 million for the quarter, compared to analysts’ expectations of $177.50 million. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 14.83%.

Trending Headlines about Emergent Biosolutions

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: Second-quarter results exceeded expectations: Emergent reported adjusted EPS of $0.60, compared with the consensus estimate of a $0.08 loss, while revenue reached $234.3 million versus expectations of $177.5 million. Emergent Biosolutions: Q2 Earnings Snapshot
• Positive Sentiment: Biodefense demand remains a potential long-term catalyst: The company highlighted increased government and public-health attention to biological threats, including geopolitical conflict, synthetic biology and the possible misuse of biological agents. Cross-Sector Collaboration Against Biological Threats
• Neutral Sentiment: Management is undertaking a restructuring: The plan is part of broader turnaround efforts and includes layoffs, signaling an attempt to reduce costs and improve operating performance, but it may also create near-term disruption and expenses. Emergent BioSolutions Announces Restructuring
• Negative Sentiment: Full-year revenue guidance was cut well below analyst expectations: Emergent now expects 2026 revenue of $645 million to $675 million, compared with the consensus estimate of approximately $730.4 million. Emergent BioSolutions Shares Plunge After 2026 Guidance Cut
• Negative Sentiment: Third-quarter guidance was also materially below expectations: Revenue is projected at $110 million to $130 million, versus analyst expectations of about $209 million. The weak forward outlook and workforce reductions are driving the negative investor reaction despite the quarterly beat. Emergent Bio Slips Despite Q2 Beat After Guidance Cut

Insider Activity at Emergent Biosolutions

In other news, SVP Paul Anthony Williams sold 3,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total value of $25,200.00. Following the completion of the sale, the senior vice president directly owned 159,098 shares of the company’s stock, valued at $1,336,423.20. This represents a 1.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Weiss Ratings lowered shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. UBS Group restated a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Finally, Benchmark reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Emergent Biosolutions currently has a consensus rating of “Hold” and a consensus target price of $12.00.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.